Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Medical Action Myanmar and MOCRU health teams identified a number of children with rickets in remote areas of Myanmar. MOCRU director Frank Smithuis presented the findings of clinical screening to the Minister of Health, alongside treatment results and a plan for a large survey to investigate the prevalence of vitamin D deficiency and its underlying causes.

After Medical Action Myanmar (MAM) / Myanmar-Oxford Clinical Research Unit (MOCRU) health teams had earlier found a number of children with characteristics of rickets in remote communities in north-west of Myanmar's Naga region on the Indian border, active screening in other villages in the region led to 182 children being identified with severe rickets.

As can be seen from the photo and the x-ray, the children, and some adults, have great difficulties walking, with some unable to walk at all. It seems that none had been diagnosed or treated earlier, possibly because their communities are extremely remote, only accessible after many hours walking.

Lab results indicated that the rickets was caused by vitamin D deficiency. Treatment with vitamin D and calcium was started immediately and follow up laboratory and X-ray investigations showed improved bone growth and bone remodelling.

After being informed of the findings, Minister of Health Dr Myint Htwe invited MAM and MOCRU to discuss the findings and local needs. On 31 May, at a follow up meeting organised by the Minister with national and regional health officials, and UN and NGO representatives, MOCRU Director Frank Smithuis presented the findings of clinical screening, patient investigations, treatment results and a plan to do a large survey in several villages in the region to investigate vitamin D deficiency prevalence and its underlying causes. The survey would include:    

  • The epidemiology and aetiology of rickets among children and pregnant women in Naga and other regions;
  • Local behaviours related to vitamin D deficiency and nutritional rickets; and
  • Potential and affordable resources of vitamin D and calcium in local communities to prevent rickets.

In addition, in cooperation with Myanmar health authorities, MOCRU/MAM proposed to:

  • Continue to screen children in Naga region and surrounding areas for rickets;
  • Treat and regularly follow up all children identified with rickets;
  • Perform blood exams and X-rays of a small patient subgroup to monitor treatment success;
  • Do community engagement to explore behaviours and raise awareness;
  • Give preventive treatment in high incidence villages for high-risk children and pregnant women.

With thanks to Frank Smithuis for text and images

Similar stories

AMR and scrub typhus among Chiangrai Unit's research priorities

Which infections are most common in the Chiangrai region? How should we treat them and how can we improve diagnostic? Which strategies are most effective in directing antibiotic treatment? Blog by Carlo Perrone, research physician based at the Chiang Rai Clinical Research Unit in Chiangrai, Thailand.

Researchers call for access to Ivermectin for young children

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

The COVID-19 vaccine: do we know enough to end the pandemic?

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.